GCP
CRBU icon

Gill Capital Partners’s Caribou Biosciences CRBU Stock Holding History

Gill Capital Partners’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$143 Buy
+75
New +$129 ﹤0.01% 668

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gill Capital Partners's CRBU Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Caribou Biosciences (CRBU) in Q1 2026: 75 shares worth $143. The stake represents ﹤0.01% of the portfolio and ranks #668 among its holdings.

137 funds tracked by Wall St. Rank hold CRBU as of Q1 2026.

  • Gill Capital Partners held 75 shares of Caribou Biosciences worth $143 as of Q1 2026.
  • Caribou Biosciences was a new Gill Capital Partners position in Q1 2026.
  • Caribou Biosciences made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #668 holding.
  • 137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.